JPRN-UMIN000022104已完成未知
Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients. - Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients.
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine0 个研究点目标入组 54 人开始时间: 2016年4月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Pregnant woman *Patients who become pregnant during study period to be required to discontinue the study 2. Patients unable to provide informed consent.
研究者
相似试验
已完成
不适用
Can fecal calprotectin be a predictive marker for refractoriness in patients with ulcerative colitis ?lcerative colitisJPRN-UMIN000024146Showa University, School of Medicine100
进行中（未招募）
不适用
Does measurement of fecal calprotectin levels help distinguish various colitis?Diseases of the digestive systemKCT0003598Eulji University Hospital30
招募中
Unknown
Study on the usefulness of fecal calprotectin in ulcerative colitis and the relevance of other biomarkerslcerative colitisJPRN-UMIN000052832Ehime University150
尚未招募
不适用
Fecal calprotectin as a predictive factor of relapse in patients with ulcerative colitis treated with tacrolimus : A prospective studyJPRN-UMIN000014714Shimane University Hospital50
已完成
不适用
The value of faecal calprotectin (CPT) in monitoring the response to treatment of patients with inflammatory bowel diseaseInflammatory bowel diseaseDigestive SystemCrohn's disease [regional enteritis]ISRCTN81965907Department of Health (UK)80